Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation High-intensity focused ultrasound (HIFU) for treatment of hepatocellular carcinoma. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2012 Authors' conclusions Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that accounts for more than 80% of all liver cancer types. HCC is an aggressive tumor that is one of the most common causes of cancer death worldwide, with an annual incidence of more than 550,000 new cases per year. The overall 5-year survival rate for HCC is 14%, and this rate decreases to 4% among patients who are diagnosed at later stages. Early-stage cancer can sometimes be treated surgically in patients with sufficient healthy liver tissue, but in more advanced stages of disease, fewer surgical options exist. Only about 5% of patients are eligible for tumor resection, which is indicated in cases with solitary tumors that are confined to the liver and normal or well-preserved liver function. Patients with localized or locally advanced, unresectable cancer may be treated with liver transplantation, percutaneous radiofrequency ablation, transarterial chemoembolization (TACE), or other forms of ablation. Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Hepatocellular; High-Intensity Focused Ultrasound Ablation; Humans Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32013000228 Date abstract record published 27/03/2013 |